Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, Marco Borderi, Linda Bussini, Isabella Bon, Maria Carla Re & Pierluigi Viale. (2017) Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infectious Diseases 49:10, pages 737-747.
Read now
Read now
Mohamed H Ahmed, Ayman Al-Atta & Mahir A Hamad. (2012) The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opinion on Pharmacotherapy 13:13, pages 1901-1909.
Read now
Read now
Julie Womack & Phyllis C Tien. (2009) Mechanisms of HIV-Related Dyslipidemia. HIV Therapy 3:3, pages 283-292.
Read now
Read now
Anthony S. Wierzbicki, Scott D. Purdon, Timothy C. Hardman, Ranjababu Kulasegaram & Barry S. Peters. (2008) HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Current Medical Research and Opinion 24:3, pages 609-624.
Read now
Read now
John E. Bury, Jeffrey S. Stroup, Johnny R. Stephens & Damon L. Baker. (2007) Achieving American Diabetes Association Goals in Hiv-Seropositive Patients with Diabetes Mellitus. Baylor University Medical Center Proceedings 20:2, pages 118-123.
Read now
Read now
Stephen Becker. (2003) Atazanavir: improving the HIV protease inhibitor class. Expert Review of Anti-infective Therapy 1:3, pages 403-413.
Read now
Read now
Karen T. Tashima, Linda Bausserman, Elizabeth Alt, Esther Aznar & Timothy P. Flanigan. (2003) Lipid Changes in Patients Initiating Efavirenz- and Indinavir-Based Antiretroviral Regimens. HIV Clinical Trials 4:1, pages 29-36.
Read now
Read now
Tashima Karen T.Bausserman Linda, Alt Elizabeth, Aznar Esther & Flanigan Timothy P.. (2003) Lipid Changes in Patients Initiating Efavirenz- and Indinavir-Based Antiretroviral Regimens. HIV Clinical Trials 4:1, pages 29-36.
Read now
Read now
Anthony S Wierzbicki. (2001) Atorvastatin. Expert Opinion on Pharmacotherapy 2:5, pages 819-830.
Read now
Read now
Articles from other publishers (74)
Yu-Lin Lee, Kuan-Yin Lin, Shu-Hsing Cheng, Po-Liang Lu, Ning-Chi Wang, Mao-Wang Ho, Chia-Jui Yang, Bo-Huang Liou, Hung-Jen Tang, Shie-Shian Huang, Sung-Hsi Huang, Tun-Chieh Chen, Chi-Ying Lin, Shih-Ping Lin, Yuan-Ti Lee & Chien-Ching Hung. (2021) Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV. International Journal of Antimicrobial Agents 58:3, pages 106403.
Crossref
Crossref
Philipe Quagliato Bellinati, Daniela Frizon Alfieri, Tamires Flauzino, Paulo Fernando Gasparetto Junior, Diogo Jorge Rossi, José Wander Breganó, Andrea Name Colado Simão, Elaine Regina Delicato de Almeida, Marcell Alysson Batisti Lozovoy & Edna Maria Vissoci Reiche. (2020) Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection. Current HIV Research 18:4, pages 292-306.
Crossref
Crossref
Suraj P. Parihar, Reto Guler & Frank Brombacher. (2018) Statins: a viable candidate for host-directed therapy against infectious diseases. Nature Reviews Immunology 19:2, pages 104-117.
Crossref
Crossref
William Andrew Clark & Eileen M. Cress. (2018) Nutritional Issues and Positive Living in Human Immunodeficiency Virus/AIDS. Nursing Clinics of North America 53:1, pages 13-24.
Crossref
Crossref
Fuu-Jen Tsai, Chi-Fung Cheng, Chih-Ho Lai, Yang-Chang Wu, Mao-Wang Ho, Jen-Hsien Wang, Ni Tien, Xiang Liu, Hsinyi Tsang, Ting-Hsu Lin, Chiu-Chu Liao, Shao-Mei Huang, Ju-Pi Li, Jung-Chun Lin, Chih-Chien Lin, Jin-Hua Chen, Wen-Miin Liang & Ying-Ju Lin. (2017) Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era. Oncotarget 8:63, pages 106369-106381.
Crossref
Crossref
Akshata Mirajkar, Shashikant Nikam, Padmaja Nikam & Giridhar Patil. (2016) Role of LCAT and Apo A-I in Newly Diagnosed HIV Patients. Indian Journal of Clinical Biochemistry 32:4, pages 459-463.
Crossref
Crossref
Lemuel R. Non, Gerome V. Escota & William G. Powderly. (2017) HIV and its relationship to insulin resistance and lipid abnormalities. Translational Research 183, pages 41-56.
Crossref
Crossref
Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, Marco Borderi, Ilaria Contadini, Isabella Bon, Maria Carla Re & Pierluigi Viale. (2017) Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients. AIDS 31:5, pages 681-688.
Crossref
Crossref
Mehmet Gokhan Culha, Ahmet Cagkan Inkaya, Emre Yildirim, Serhat Unal & Ege Can Serefoglu. (2016) Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy. Medical Hypotheses 94, pages 151-153.
Crossref
Crossref
Leonardo Calza, Vincenzo Colangeli, Roberto Manfredi, Isabella Bon, Maria Carla Re & Pierluigi Viale. (2016) Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. Journal of Antimicrobial Chemotherapy 71:6, pages 1451-1465.
Crossref
Crossref
Jonathan T. DaviesSpencer F. DelfinoChad E. FeinbergMeghan F. JohnsonVeronica L. NappiJoshua T. OlingerAnthony P. SchwabHollie I. Swanson. (2016) Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights 9, pages LPI.S37450.
Crossref
Crossref
T Heikinheimo, E Poutiainen, O Salonen, I Elovaara & M Ristola. (2015) Three-decade neurological and neurocognitive follow-up of HIV-1-infected patients on best-available antiretroviral therapy in Finland. BMJ Open 5:11, pages e007986.
Crossref
Crossref
Nazisa Hejazi & Roslee Rajikan. 2015. Health of HIV Infected People. Health of HIV Infected People
17
49
.
Frederick J. Lee & Andrew Carr. 2015. Dyslipidemias. Dyslipidemias
155
176
.
Mohammed K. Ali, Matthew J. Magee, Joel A. Dave, Igho Ofotokun, Marisa Tungsiripat, Trammell K. Jones, Naomi S. Levitt, David Rimland & Wendy S. Armstrong. (2014) HIV and Metabolic, Body, and Bone Disorders. JAIDS Journal of Acquired Immune Deficiency Syndromes 67:Supplement 1, pages S27-S39.
Crossref
Crossref
Maria Ferrara, Anya Umlauf, Chelsea Sanders, Jonathan M. Meyer, John Allen McCutchan, Nichole Duarte, Joseph Hampton Atkinson, Igor Grant & Ronald J. Ellis. (2014) The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Research 218:1-2, pages 201-208.
Crossref
Crossref
Gerard Wong, Janine M. Trevillyan, Benoit Fatou, Michelle Cinel, Jacquelyn M. Weir, Jennifer F. Hoy & Peter J. Meikle. (2014) Plasma Lipidomic Profiling of Treated HIV-Positive Individuals and the Implications for Cardiovascular Risk Prediction. PLoS ONE 9:4, pages e94810.
Crossref
Crossref
Robert A. Ngala & Klutse Fianko. (2014) Effects of HIV Infection and Anti-retroviral Therapy on Cardiovascular Risk Factors. Trends in Molecular Sciences 6:1, pages 1-12.
Crossref
Crossref
Janine M Trevillyan & Jennifer F Hoy. (2014) Protecting the heart after HAART; understanding the pathogenesis of cardiovascular disease in people living with HIV. Microbiology Australia 35:2, pages 91.
Crossref
Crossref
Davis Kibirige & Richard Ssekitoleko. (2013) Endocrine and metabolic abnormalities among HIV-infected patients: A current review. International Journal of STD & AIDS 24:8, pages 603-611.
Crossref
Crossref
Elaine Regina Delicato de Almeida, Edna Maria Vissoci Reiche, Ana Paula Kallaur, Tamires Flauzino & Maria Angelica Ehara Watanabe. (2013) The Roles of Genetic Polymorphisms and Human Immunodeficiency Virus Infection in Lipid Metabolism. BioMed Research International 2013, pages 1-15.
Crossref
Crossref
Guoping Hu, Xi Li, Xianqiang Sun, Weiqiang Lu, Guixia Liu, Jin Huang, Xu Shen & Yun Tang. (2012) Identification of old drugs as potential inhibitors of HIV-1 integrase – human LEDGF/p75 interaction via molecular docking. Journal of Molecular Modeling 18:12, pages 4995-5003.
Crossref
Crossref
Joo-Pin Foo & Christos S. Mantzoros. (2012) Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials. Metabolism 61:10, pages 1331-1336.
Crossref
Crossref
Jeroen P. H. van Wijk & Manuel Castro Cabezas. (2012) Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. International Journal of Vascular Medicine 2012, pages 1-13.
Crossref
Crossref
Christine B. Bruno, Jeffrey M. Schapiro & Parya Saberi. (2011) An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual. Journal of the International Association of Physicians in AIDS Care 10:4, pages 219-222.
Crossref
Crossref
T. Bommenel, O. Launay, J. L. Meynard, J. Gilquin, C. Katlama, A. S. Lascaux, A. Mahamat, V. Martinez, C. Pradier, E. Rouveix, A. Simon, D. Costagliola, S. Abgrall, S. Abgrall, F. Barin, M. Bentata, E. Billaud, F. Boue, C. Burty, A. Cabie, D. Costagliola, L. Cotte, P. de Truchis, X. Duval, C. Duvivier, P. Enel, J. Gasnault, C. Gaud, J. Gilquin, S. Grabar, C. Katlama, M. A. Khuong, J. M. Lang, A. S. Lascaux, O. Launay, A. Mahamat, M. Mary-Krause, S. Matheron, J. L. Meynard, J. Pavie, G. Pialoux, F. Pilorge, I. Poizot-Martin, C. Pradier, J. Reynes, E. Rouveix, A. Simon, P. Tattevin, H. Tissot-Dupont, J. P. Viard, N. Viget, M. Brosseau, V. Salomon, N. Jacquemet, M. Guiguet, E. Lanoy, L. Lievre, H. Selinger-Leneman, J. M. Lacombe, V. Potard, F. Bricaire, S. Herson, N. Desplanque, P. M. Girard, M. C. Meyohas, O. Picard, J. Cadranel, C. Mayaud, J. P. Clauvel, J. M. Decazes, L. Gerard, J. M. Molina, M. Diemer, P. Sellier, P. Honore, V. Jeantils, S. Tassi, D. Mechali, B. Taverne, E. Bouvet, B. Crickx, J. L. Ecobichon, C. Picard-Dahan, P. Yeni, H. Berthe, C. Dupont, C. Chandemerle, E. Mortier, D. Tisne-Dessus, L. Weiss, D. Salmon, I. Auperin, L. Roudiere, R. Fior, J. F. Delfraissy, C. Goujard, C. Jung, P. Lesprit, D. Vittecoq, P. Fraisse, D. Rey, G. Beck-Wirth, J. P. Stahl, P. Lecercq, F. Gourdon, H. Laurichesse, A. Fresard, F. Lucht, C. Bazin, R. Verdon, P. Chavanet, C. Arvieux, C. Michelet, P. Choutet, A. Goudeau, M. F. Maitre, B. Hoen, P. Elinger, J. P. Faller, F. Borsa-Lebas, F. Caron, J. P. Daures, T. May, C. Rabaud, J. L. Berger, G. Remy, E. Arlet-Suau, L. Cuzin, P. Massip, M. F. Thiercelin Legrand, G. Pontonnier, Y. Yasdanpanah, P. Dellamonica, P. Pugliese, K. Aleksandrowicz, D. Quinsat, I. Ravaux, J. P. Delmont, J. Moreau, J. A. Gastaut, F. Retornaz, J. Soubeyrand, A. Galinier, J. M. Ruiz, T. Allegre, P. A. Blanc, D. Bonnet-Montchardon, G. Lepeu, P. Granet-Brunello, J. P. Esterni, L. Pelissier, R. Cohen-Valensi, M. Nezri, S. Chapadaud, A. Laffeuillade, F. Raffi, A. Boibieux, D. Peyramond, J. M. Livrozet, J. L. Touraine, C. Trepo, M. Strobel, F. Bissuel, R. Pradinaud, M. Sobesky & M. Contant. (2011) Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. Journal of Antimicrobial Chemotherapy 66:8, pages 1869-1877.
Crossref
Crossref
Kristine A. Scordo. (2010) Treating antiretroviral-induced dyslipidemia in HIV-infected adults. The Nurse Practitioner 35:7, pages 32-37.
Crossref
Crossref
Erdembileg AnuuradAlison SemradLars Berglund. (2009) Human Immunodeficiency Virus and Highly Active Antiretroviral Therapy–Associated Metabolic Disorders and Risk Factors for Cardiovascular Disease. Metabolic Syndrome and Related Disorders 7:5, pages 401-409.
Crossref
Crossref
G Ferns, V Keti & B Griffin. (2008) Investigation and management of hypertriglyceridaemia. Journal of Clinical Pathology 61:11, pages 1174-1183.
Crossref
Crossref
Anthony S WierzbickiScott D Purdon, Timothy C Hardman, Ranjababu Kulasegaram & Barry S Peters. (2008) Review: Clinical aspects of the management of HIV lipodystrophy. The British Journal of Diabetes & Vascular Disease 8:3, pages 113-119.
Crossref
Crossref
Jean-Marc PascussiSabine Gerbal-ChaloinCédric DuretMartine Daujat-ChavanieuMarie-José VilaremPatrick Maurel. (2008) The Tangle of Nuclear Receptors that Controls Xenobiotic Metabolism and Transport: Crosstalk and Consequences. Annual Review of Pharmacology and Toxicology 48:1, pages 1-32.
Crossref
Crossref
Jisun Oh & Robert A Hegele. (2007) HIV-associated dyslipidaemia: pathogenesis and treatment. The Lancet Infectious Diseases 7:12, pages 787-796.
Crossref
Crossref
John M. TovarDebora B. Schering. (2016) Management of Dyslipidemia in Special Populations. Journal of Pharmacy Practice 19:2, pages 63-78.
Crossref
Crossref
Magali Prod’homme, Cécile Rochon, Michèle Balage, Henri Laurichesse, Igor Tauveron, Claude Champredon, Philippe Thieblot, Jean Beytout & Jean Grizard. (2006) Whole body leucine flux in HIV-infected patients treated with or without protease inhibitors. American Journal of Physiology-Endocrinology and Metabolism 290:4, pages E685-E693.
Crossref
Crossref
J. G. Jemsek, E. Arathoon, M. Arlotti, C. Perez, N. Sosa, V. Pokrovskiy, A. Thiry, M. Soccodato, M. A. Noor & M. Giordano. (2006) Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV-Infected Patients. Clinical Infectious Diseases 42:2, pages 273-280.
Crossref
Crossref
Ly Q. Hong-BrownC. Randell BrownCharles H. Lang. (2005) HIV Antiretroviral Agents Inhibit Protein Synthesis and Decrease Ribosomal Protein S6 and 4EBP1 Phosphorylation in C2C12 Myocytes. AIDS Research and Human Retroviruses 21:10, pages 854-862.
Crossref
Crossref
B. Chanu & P. Valensi. (2005) Les désordres lipidiques des patients atteints d’affections causées par le VIH. La Presse Médicale 34:15, pages 1087-1094.
Crossref
Crossref
Jim Young, Rainer Weber, Martin Rickenbach, Hansjakob Furrer, Enos Bernasconi, Bernard Hirschel, Philip E Tarr, Pietro Vernazza, Manuel Battegay, Heiner C Bucher, M Battegay, E Bernasconi, J Böni, H Bucher, Ph Bürgisser, S Cattacin, M Cavassini, R Dubs, M Egger, L Elzi, P Erb, K Fantelli, M Fischer, M Flepp, A Fontana, P Francioli, H Furrer, M Gorgievski, H Günthard, B Hirschel, L Kaiser, C Kind, Th Klimkait, U Lauper, B Ledergerber, M Opravil, F Paccaud, G Pantaleo, L Perrin, J-C Piffaretti, C Rudin, P Schmid, J Schüpbach, R Speck, A Telenti, A Trkola, P Vernazza, R Weber & S Yerly. (2005) Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. Antiviral Therapy 10:5, pages 585-591.
Crossref
Crossref
Clotilde Allavena, Virginie Ferré, Cécile Brunet-François, Jean-François Delfraissy, Alain Lafeuillade, Marc-Antoine Valantin, Michelle Bentata, Christian Michelet, Isabelle Poizot-Martin, Eric Dailly, Odile Launay & François Raffi. (2005) Efficacy and Tolerability of a Nucleoside Reverse Transcriptase Inhibitor-Sparing Combination of Lopinavir/Ritonavir and Efavirenz in HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 39:3, pages 300-306.
Crossref
Crossref
Margaret Johnson, Beatriz Grinsztejn, Claudia Rodriguez, Jeffrey Coco, Edwin DeJesus, Adriano Lazzarin, Kenneth Lichtenstein, Anna Rightmire, Serap Sankoh & Richard Wilber. (2005) Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19:7, pages 685-694.
Crossref
Crossref
James D. Scott. (2005) Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. American Journal of Health-System Pharmacy 62:8, pages 809-815.
Crossref
Crossref
William B. Kannel & Michael Giordano. (2004) Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. The American Journal of Cardiology 94:7, pages 901-906.
Crossref
Crossref
Pedro E. Cahn, José M. Gatell, Kathleen Squires, Lisa D. Percival, Peter J. Piliero, Ian A. Sanne, Sarah Shelton, Adriano Lazzarin, Linda Odeshoo, Thomas D. Kelleher, Alexandra Thiry, Michael D. Giordano & Stephen M. Schnittman. (2016) Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials. Journal of the International Association of Physicians in AIDS Care 3:3, pages 92-98.
Crossref
Crossref
Esteban Martínez, Montserrat Tuset, Ana Milinkovic, José M Miró & José M Gatell. (2004) Management of Dyslipidaemia in HIV-Infected Patients Receiving Antiretroviral Therapy. Antiviral Therapy 9:5, pages 649-663.
Crossref
Crossref
Zhijun Zhang, Robert Hamatake & Zhi Hong. (2016) Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under Development. Antiviral Chemistry and Chemotherapy 15:3, pages 121-134.
Crossref
Crossref
Juan F Ascaso, Arturo Fern??ndez-Cruz, Pedro Gonz??lez Santos, Antonio Hern??ndez Mijares, Alipio Mangas Rojas, Jesus Mill??n, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco P??rez-Jim??nez, Gonzalo P??a, Xavier Pint??Ignacio Plaza & Juan Rubi??s-Prat. (2004) Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention. American Journal of Cardiovascular Drugs 4:5, pages 299-314.
Crossref
Crossref
Joseph P. Colagreco. (2004) Cardiovascular Considerations in Patients Treated with HIV Protease Inhibitors. Journal of the Association of Nurses in AIDS care 15:1, pages 30-41.
Crossref
Crossref
F. Patrick Robinson. (2004) HIV Lipodystrophy Syndrome: A Primer. Journal of the Association of Nurses in AIDS care 15:1, pages 15-29.
Crossref
Crossref
Ascaso J.F.Fernández-Cruz A.González Santos P.Hernández Mijares A.Mangas Rojas A.Millán J.Pallardo L.F.J. Pedro-Botet, Pérez-Jiménez F.Pía G.X. Pintó, I. Plaza & J. Rubiés-Prat. (2004) Importancia del colesterol ligado a lipoproteínas de alta densidad (cHDL) en la prevención del riesgo cardiovascular. Recomendaciones del Foro HDL. Clínica e Investigación en Arteriosclerosis 16:6, pages 262-280.
Crossref
Crossref
William H. Frishman, Aysha Arshad & Ajay Bansal. 2004. AIDS and Other Manifestations of HIV Infection. AIDS and Other Manifestations of HIV Infection
635
649
.
Robert L Murphy, Ian Sanne, Pedro Cahn, Praphan Phanuphak, Lisa Percival, Thomas Kelleher & Michael Giordano. (2003) Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects. AIDS 17:18, pages 2603-2614.
Crossref
Crossref
Esteban Martínez, Juan A. Arnaiz, Daniel Podzamczer, David Dalmau, Esteban Ribera, Pere Domingo, Hernando Knobel, Melcior Riera, Enric Pedrol, Lluis Force, Josep M. Llibre, Ferran Segura, Cristóbal Richart, Cristina Cortés, Manuel Javaloyas, Miquel Aranda, Ana Cruceta, Elisa de Lazzari & José M. Gatell. (2003) Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine 349:11, pages 1036-1046.
Crossref
Crossref
Luc F. Van Gaal, Ilse L. Mertens & Pascale J. Abrams. (2003) Health risks of lipodystrophy and abdominal fat accumulation: therapeutic possibilities with leptin and human growth hormone. Growth Hormone & IGF Research 13, pages S4-S9.
Crossref
Crossref
Leonardo Calza, Roberto Manfredi & Francesco Chiodo. (2003) Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. International Journal of Antimicrobial Agents 22:2, pages 89-99.
Crossref
Crossref
David W Haas, Carlos Zala, Shannon Schrader, Peter Piliero, Hans Jaeger, Danilo Nunes, Alexandra Thiry, Steven Schnittman & Michael Sension. (2003) Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 17:9, pages 1339-1349.
Crossref
Crossref
Leonardo Calza, Roberto Manfredi & Francesco Chiodo. (2003) Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 17:6, pages 851-859.
Crossref
Crossref
Vincent Mooser. (2003) Atherosclerosis and HIV in the highly active antiretroviral therapy era. AIDS 17, pages S65-S69.
Crossref
Crossref
Lal K. Tanwani & SriPrakash L. Mokshagundam. (2003) Lipodystrophy, Insulin Resistance, Diabetes Mellitus, Dyslipidemia, and Cardiovascular Disease in Human Immunodeficiency Virus Infection. Southern Medical Journal 96:2, pages 180-188.
Crossref
Crossref
Marc van der Valk & Peter Reiss. (2003) Lipid profiles associated with antiretroviral drug choices. Current Opinion in Infectious Diseases 16:1, pages 19-23.
Crossref
Crossref
Ian Sanne, Peter Piliero, Kathleen Squires, Alexandra Thiry & Steven Schnittman. (2003) Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes 32:1, pages 18-29.
Crossref
Crossref
Stefania Lamon-Fava & Ernst J. Schaefer. 2003. Lipodystrophy Syndrome in HIV. Lipodystrophy Syndrome in HIV
87
105
.
. (2002) References. Circulation 106:25, pages 3373-3421.
Crossref
Crossref
Rosario Palacios, Jesús Santos, Mercedes González, Josefa Ruiz, Pedro Valdivielso, Manuel Márquez & Pedro González-Santos. (2002) Efficacy and Safety of Fenofibrate for the Treatment of Hypertriglyceridemia Associated With Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 31:2, pages 251-253.
Crossref
Crossref
Qingyi Meng, Joao A.C. Lima, Hong Lai, David Vlahov, David D. Celentano, Steffanie A. Strathdee, Kenrad E. Nelson, Katherine C. Wu, Shaoguang Chen, Wenjing Tong & Shenghan Lai. (2002) Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. American Heart Journal 144:4, pages 642-648.
Crossref
Crossref
Rosario Palacios, Jesús Santos, Mercedes González, Josefa Ruiz, Pedro Valdivielso, Manuel Márquez & Pedro González-Santos. (2002) Efficacy and Safety of Atorvastatin in the Treatment of Hypercholesterolemia Associated With Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 30:5, pages 536-537.
Crossref
Crossref
Christoph Handschin, Michael Podvinec, Remo Amherd, Renate Looser, Jean-Claude Ourlin & Urs A. Meyer. (2002) Cholesterol and Bile Acids Regulate Xenosensor Signaling in Drug-mediated Induction of Cytochromes P450. Journal of Biological Chemistry 277:33, pages 29561-29567.
Crossref
Crossref
Stephen C. Piscitelli, Aaron H. Burstein, Nada Welden, Keith D. Gallicano & Judith Falloon. (2002) The Effect of Garlic Supplements on the Pharmacokinetics of Saquinavir. Clinical Infectious Diseases 34:2, pages 234-238.
Crossref
Crossref
J. Rubiés-Prat. (2002) Hiperlipoproteinemias secundarias. Clínica e Investigación en Arteriosclerosis 14:3, pages 142-149.
Crossref
Crossref
VINCENZO PURO, GABRIELLA DE CARLI, PAOLA SCOGNAMIGLIO, ROLANDO PORCASI & GIUSEPPE IPPOLITO. (2006) Risk of HIV and Other Blood‐Borne Infections in the Cardiac Setting. Annals of the New York Academy of Sciences 946:1, pages 291-309.
Crossref
Crossref
Michael H. Davidson. (2016) Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions. Journal of Cardiovascular Pharmacology and Therapeutics 6:3, pages 219-229.
Crossref
Crossref
Paul W. Hruz, Haruhiko Murata & Mike Mueckler. (2001) Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. American Journal of Physiology-Endocrinology and Metabolism 280:4, pages E549-E553.
Crossref
Crossref
Harinder S. Malhotra & Karen L. Goa. (2001) Atorvastatin. Drugs 61:12, pages 1835-1881.
Crossref
Crossref
R. Manfredi. (2000) Management of dyslipidemia in patients with HIV disease. Clinical Microbiology and Infection 6:11, pages 579-584.
Crossref
Crossref
. (2000) Current Awareness. Pharmacoepidemiology and Drug Safety 9:6, pages 533-548.
Crossref
Crossref